Progress in Research on Intestinal Absorption Mechanism of Milk-derived ACE Inhibitory Peptides Using Caco-2 Cell Model

doi:10.7506/spkx1002-6630-201309066

Abstract

Abstract:

The specific active peptides in milk can inhibit the activity of angiotensinⅠ-converting enzyme effectively
to execute antihypertensive effect. Due to different structures of milk-derived ACE inhibitory peptides, the peptides
are not able to pass through the intestinal mucosa into blood circulation when administered orally. Therefore, not
all ACE inhibitory peptides have the function of lowering blood pressure and a low oral bioavailability. This article
has introduced current research status and activity evaluation as well as the intestinal absorption mechanism of milkderived
ACE inhibitory peptides, which includes intestinal ingestion, metabolic activity and intestinal excretion using
Caco-2 cell model. In addition, a prospect of improving oral bioavailability of milk-derived ACE inhibitory peptides
has also been proposed.

Key words: Caco-2 cell model, milk-derived ACE inhibitory peptide, absorption mechanism of peptide

CLC Number:

TS252.1

ZHU Qian1，GUO Yu-xing1,*，PAN Dao-dong1,2. Progress in Research on Intestinal Absorption Mechanism of Milk-derived ACE Inhibitory Peptides Using Caco-2 Cell Model[J]. FOOD SCIENCE, 2013, 34(9): 330-335.

References

[1] 何海伦, 陈秀兰. 血管紧张素转化酶抑制肽的研究进展[J]. 中国生物工程杂志, 2004,24 (9):7-11.
[2] 曹文红，章超桦. 生物活性肽的吸收机制[J]. 药物生物技术, 2006,13(5):384~388.
[3] 郭慧青, 毛慧, 赵波等. 两种血管紧张素转化酶抑制肽作用于靶标的分子机理[J]. 食品科学, 2010, 31(23):1-5.
[4] FERREIRA S H. A bradykinin-potent iating fact or ( BPF) present in the venom of Bothrops jararaca[J]. Brit J Pharmacol, 1965, 24: 163~169.
[5] OSHIMA G, SHIMABUKURO H, NAGASAWA K. Peptide inhibitors of angiotensin-converting enzyme in digests of gelatin by bacterial collagenase [J]. Biochimicaet Biohysica Acta, 1979, 566:128-137.
[6] BLANCA H L, MARíA M C, ISIDRA R. Antihypertensive peptides: Production, bioavailability and incorporation into foods[J]. Advances in Colloid and Interface Science, 2011, 165:23-35.
[7] NAKAMURA Y, YAMAMOTO N, SAKAI K, et al. Purification and characterization of angiotensin-I converting enzyme inhibitors from sour milk[J]. J Dairy Sci, 1995, 74(8): 777-783.
[8] YAMAMOTO N., TAKANO T. Antihypertensive peptides derived from milk proteins[J]. Molecular Nutrition and Food Research, 1999, 43(3):159-164.
[9] YAMAMOTO N, AKINO A, TAKANO T. Purification and specificity of a cell-wall associated proteinase from Lactobacillus helveticus CP790[J]. Journal of Biochemistry, 1993, 114: 740-745.
[10] LAPOINTE J F, GAUTHIER S F, POULIOT Y, et al. Selective Separation of Cationic Peptides From a Tryptic Hydrolysate of β-Lactoglobulin by Electrofiltration[DB/OL]. (2006) www.interscience.wiley.com.
[11] MAVAYAMAS S，SUZUKI H. A peptide inhibitor of angiotensin converting enzyme by synthetic petides of human of casein［J］. Agric Biolchem, 2002, 46( 5) : 1393.
[12] 季闽春, 王永铭, 陈斌艳. 血管紧张素转化酶抑制剂的皮肤不良反应[J]. 中国临床药理学杂志, 1996, 12: 112- 114.
[13] 许金光,杨智超,刘长江. 血管紧张素转化酶（ACE）抑制肽的研究进展[J]. 食品工业科技, 2011, 32(5):425-427.
[14] 管骁，彭剑秋，金周筠,等.食源性血管紧张素转化酶抑制肽的研究[J].食品与发酵工业, 2011, 37( 7 ):135-141.
[15] SHAH P, JOGANI V, BAGCHI T, et al. Role of Caco-2 cell monolayers in prediction of intestinal drug absorption[J]. Biotechnol Prog, 2006, 22:186－198.
[16] ARTURSSON P , PALM K, LUTHMAN K. Caco2 monolayers in experimental and theoretical predictions of drug transport[J] . Advanced Drug Delivery Reviews , 1996 , 22 : 67-84.
[17] 关溯, 综述, 陈孝. Caco-2细胞模型---药物吸收研究的有效“工具”[J]. 中国药理学通报, 2004 , 20( 6) : 609-614.
[18] 孙勇兵,孙进,何仲贵. 小肠寡肽转运蛋白及其在提高药物口服吸收中的应用[J]. 中国新药与临床杂志, 2006, 25(10):776-782.
[19] SATAKE M, ENJOH M, NAKAMURA Y, et al. Transepithelial transport of the bioactive tripeptide Val-Pro-Pro, in human intestinal Caco-2 cell monolayers[J]. Bioscience Biotechnology and Biochemistry, 2002, 66, 378-384.
[20] 刘冬, 孙海燕, 雷林,等. 降血压肽 Val-Leu-Pro-Val-Pro 在 Caco-2 细胞模型中的吸收机制[J]. 营养学报, 2008,30(4):354-362.
[21] PAPPENHEIMER JR, DAHL C E, KARNOVSKY M L, et al. Intestinal absorption and excretion of octapeptides composed of D-amino acids[J]. Proc.Natl.Acad.Sci, 1994, 91:1942-1945.
[22] ADSON A, RAUB T J, BURTON P S, et al. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers[J]. Pharm. Sci, 1994,83:1529-1536.
[23] SHIMIZU M, TSUNOGAI M, ARAI S. Transepithelial transport of oligopeptides in the human intestinal cell caco-2[J]. Peptides, 1997, 18:681-687.
[24] ANA Q, ALBERTO D, MIGUEL A. et al. Bioavailability of the antihypertensive peptide LHLPLP: Transepithelial flux of HLPLP[J]. International Dairy Journal, 2008, (18):279–286.
[25] 廖晓慧, 孙海燕, 彭光华,等. Caco-2细胞模型及其在食品营养物质吸收研究中的新进展[J]. 农产品加工学刊, 2007, 2:37-40.
[26] RIEKO A, YUKITAKA K, MOTOHIRO S, et al. Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability[J]. Bioorganic & Medicinal Chemistry, 2004, (12): 257–264.
[27] VERMEIRSSEN V, DEPLANCKE B, TAPPENDEN K A, et al. Intestinal Transport of the Lactokinin
Ala-Leu-Pro-Met-His-Ile-Arg through a Caco-2 Bbe Monolayer[J]. Journal of Peptide Science , 2002, 8: 95–100.
[28] 卢智玲, 冯怡, 徐德生,等. Caco-2细胞模型在中药口服吸收及机制研究中的应用[J]. 中草药, 2006, 37(4):616-619.
[29] 郑慧娜,章超桦,吉宏武. 马氏珠母贝高F值寡肽在Caco-2 细胞中吸收的初步研究[J]. 食品与生物技术学报, 2011,30(4):613-617.
[30] 杨超，尹宗宁. 提高酶和多肽类药物口服吸收方法及机制的研究进展[J]. 中国新药杂志, 2006,15(12):945-948.